1. |
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: A report from the American Heart Association. Circulation, 2020, 141(9): e139-e596.
|
2. |
Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: Pathophysiology and therapy. Circulation, 2000, 101(25): 2981-2988.
|
3. |
Anderson JL, Morrow DA. Acute myocardial infarction. N Engl J Med, 2017, 376(21): 2053-2064.
|
4. |
Yu H, Lu K, Zhu J, et al. Stem cell therapy for ischemic heart diseases. Br Med Bull, 2017, 121(1): 135-154.
|
5. |
Laflamme MA, Murry CE. Heart regeneration. Nature, 2011, 473(7347): 326-335.
|
6. |
Cahill TJ, Choudhury RP, Riley PR. Heart regeneration and repair after myocardial infarction: Translational opportunities for novel therapeutics. Nat Rev Drug Discov, 2017, 16(10): 699-717.
|
7. |
Karagiannis P, Takahashi K, Saito M, et al. Induced pluripotent stem cells and their use in human models of disease and development. Physiol Rev, 2019, 99(1): 79-114.
|
8. |
Burridge PW, Matsa E, Shukla P, et al. Chemically defined generation of human cardiomyocytes. Nat Methods, 2014, 11(8): 855-860.
|
9. |
Gerecht-Nir S, Radisic M, Park H, et al. Biophysical regulation during cardiac development and application to tissue engineering. Int J Dev Biol, 2006, 50(2-3): 233-243.
|
10. |
Iberite F, Gruppioni E, Ricotti L. Skeletal muscle differentiation of human iPSCs meets bioengineering strategies: Perspectives and challenges. NPJ Regen Med, 2022, 7(1): 23.
|
11. |
Csobonyeiova M, Polak S, Nicodemou A, et al. iPSCs in modeling and therapy of osteoarthritis. Biomedicines, 2021, 9(2): 186.
|
12. |
Nguyen R, Da Won Bae S, Qiao L, et al. Developing liver organoids from induced pluripotent stem cells (iPSCs): An alternative source of organoid generation for liver cancer research. Cancer Lett, 2021, 508: 13-17.
|
13. |
Van Lent J, Verstraelen P, Asselbergh B, et al. Induced pluripotent stem cell-derived motor neurons of CMT type 2 patients reveal progressive mitochondrial dysfunction. Brain, 2021, 144(8): 2471-2485.
|
14. |
Kerr CM, Richards D, Menick DR, et al. Multicellular human cardiac organoids transcriptomically model distinct tissue-level features of adult myocardium. Int J Mol Sci, 2021, 22(16): 8482.
|
15. |
Streeter BW, Davis ME. Therapeutic cardiac patches for repairing the myocardium. Germany: Springer International Publishing, 2018: 1-24.
|
16. |
Siddiqui N, Asawa S, Birru B, et al. PCL-based composite scaffold matrices for tissue engineering applications. Mol Biotechnol, 2018, 60(7): 506-532.
|
17. |
Sowmya B, Hemavathi AB, Panda PK. Poly (ε-caprolactone)-based electrospun nano-featured substrate for tissue engineering applications: A review. Prog Biomater, 2021, 10(2): 91-117.
|
18. |
Hendrickson T, Mancino C, Whitney L, et al. Mimicking cardiac tissue complexity through physical cues: A review on cardiac tissue engineering approaches. Nanomedicine, 2021, 33: 102367.
|
19. |
Wanjare M, Hou L, Nakayama KH, et al. Anisotropic microfibrous scaffolds enhance the organization and function of cardiomyocytes derived from induced pluripotent stem cells. Biomater Sci, 2017, 5(8): 1567-1578.
|
20. |
Sridharan D, Palaniappan A, Blackstone BN, et al. In situ differentiation of human-induced pluripotent stem cells into functional cardiomyocytes on a coaxial PCL-gelatin nanofibrous scaffold. Mater Sci Eng C Mater Biol Appl, 2021, 118: 111354.
|
21. |
Rachel K, Pathak S, Moorthi A, et al. 5-Azacytidine incorporated polycaprolactone-gelatin nanoscaffold as a potential material for cardiomyocyte differentiation. J Biomater Sci Polym Ed, 2020, 31(1): 123-140.
|
22. |
Rosenblatt-Velin N, Lepore MG, Cartoni C, et al. FGF-2 controls the differentiation of resident cardiac precursors into functional cardiomyocytes. J Clin Invest, 2005, 115(7): 1724-1733.
|
23. |
Ramesh S, Govarthanan K, Ostrovidov S, et al. Cardiac differentiation of mesenchymal stem cells: Impact of biological and chemical inducers. Stem Cell Rev Rep, 2021, 17(4): 1343-1361.
|
24. |
Anderson ME, Goldhaber J, Houser SR, et al. Embryonic stem cell-derived cardiac myocytes are not ready for human trials. Circ Res, 2014, 115(3): 335-338.
|
25. |
Chong JJ, Yang X, Don CW, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature, 2014, 510(7504): 273-277.
|
26. |
Xu SJ, Mu JS, Zhang JQ, et al. In vitro three-dimensional coculturing poly3-hydroxybutyrate-co-3-hydroxyhexanoate with mouse-induced pluripotent stem cells for myocardial patch application. J Biomater Appl, 2016, 30(8): 1273-1282.
|
27. |
Zhang Z, Zhou F, Zheng J, et al. Preparation of myocardial patches from DiI-labeled rat bone marrow mesenchymal stem cells and neonatal rat cardiomyocytes contact co-cultured on polycaprolactone film. Biomed Mater, 2022, 17(4): 045015.
|
28. |
Niu H, Mu J, Zhang J, et al. Comparative study of three types of polymer materials co-cultured with bone marrow mesenchymal stem cells for use as a myocardial patch in cardiomyocyte regeneration. J Mater Sci Mater Med, 2013, 24(6): 1535-1542.
|
29. |
Tan X, Dai Q, Guo T, et al. Efficient generation of transgene- and feeder-free induced pluripotent stem cells from human dental mesenchymal stem cells and their chemically defined differentiation into cardiomyocytes. Biochem Biophys Res Commun, 2018, 495(4): 2490-2497.
|
30. |
Jiang Y, Li X, Guo T, et al. Ranolazine rescues the heart failure phenotype of PLN-deficient human pluripotent stem cell-derived cardiomyocytes. Stem Cell Reports, 2022, 17(4): 804-819.
|